摘要
肺癌恶性程度高,是目前发病率和死亡率居首位的恶性肿瘤,其中非小细胞肺癌约占肺癌的80%~85%,且多数患者在确诊时已属晚期。随着对肿瘤发病机制及其生物学行为研究的不断深入,以特异性高、不良反应轻为特点的分子靶向治疗成为目前关注的焦点,如针对EGFR、KRAS及EML4-ALK融合基因等常见突变基因的靶向治疗。但是由于基因检测技术、组织标本获取困难等多种原因,致使大约70%以上的晚期非小细胞肺癌患者不能够接受基因靶向治疗,本文就晚期非小细胞肺癌靶向治疗进行综述。
Lung cancer is high malignant,with the most morbidity and mortality currently,including non-small cell lung cancer（NSCLC） accounts for about 80%to 85%of lung cancer,and most patients are diagnosed at advanced stage.With the deepening research of tumor pathogenesis and biological behavior,molecular targeted therapy characterized by high specificity and mild adverse reactions has become the focus of current concern,such as the therapy targeted at EGFR,KRAS,and EML4-ALK fusion genes mutations.However,due to genetic testing,tissue samples and other difficulties,resulting in over about 70%of advanced NSCLC patients can not accept targeted gene therapy.This article reviewed the targeted therapy of advanced NSCLC.
出处
《中华临床医师杂志（电子版）》
CAS
2016年第2期264-269,共6页
Chinese Journal of Clinicians(Electronic Edition)
关键词
癌
非小细胞肺
基因突变
靶向治疗
Carcinoma
non-small-cell lung
DNA mutations
Targeted therapy
